CREATE Medicines to Host APLAR 2026 Workshop and Present on In Vivo CAR-T
CREATE Medicines plans a pre-congress workshop and presentation on in vivo CAR-T for autoimmune disease at APLAR 2026.
Related stories
Integer Holdings Reports Third-Quarter 2026 Results
M impact | EQUITY | Oct 29, 2026, 12:11 PM UTC
Federal Signal reports Q3 revenue of $655.5 million
Q3 revenue was $655.5 million, versus a FactSet estimate of $661.6 million.
M impact | EQUITY | Oct 29, 2026, 12:05 PM UTC
Fluent to Report Third-Quarter 2026 Results on November 12
Fluent says it will announce its third-quarter 2026 financial results and host an earnings conference call on November 12, 2026.
M impact | EQUITY | Oct 29, 2026, 12:05 PM UTC
Alnylam Reports Q3 Revenue of $1.46B
Alnylam reported Q3 revenue of $1.46 billion, versus a FactSet estimate of $1.43 billion.
M impact | EQUITY | Oct 29, 2026, 12:05 PM UTC
Sundaram Home Finance Q2 Net Profit Rises 20% to ₹90 Crore
Net profit for the quarter ended September 30, 2026, rose from ₹75 crore a year earlier. Overall disbursements were ₹2,199 crore, compared with ₹1,681 crore.
M impact | EQUITY | Oct 29, 2026, 12:05 PM UTC
Boralex Agrees to Acquire UK Renewable Energy Developer
Boralex agreed to acquire Wind2, a UK-based renewable energy developer.
M impact | EQUITY | Oct 29, 2026, 12:05 PM UTC